X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES LUPIN LTD ALKEM LABORATORIES/
LUPIN LTD
 
P/E (TTM) x - 16.8 - View Chart
P/BV x 6.1 3.9 156.5% View Chart
Dividend Yield % 0.7 0.8 89.9%  

Financials

 ALKEM LABORATORIES   LUPIN LTD
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
LUPIN LTD
Mar-16
ALKEM LABORATORIES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,5892,127 74.7%   
Low Rs1,2321,294 95.2%   
Sales per share (Unadj.) Rs417.5304.1 137.3%  
Earnings per share (Unadj.) Rs56.350.4 111.7%  
Cash flow per share (Unadj.) Rs64.760.7 106.6%  
Dividends per share (Unadj.) Rs12.707.50 169.3%  
Dividend yield (eoy) %0.90.4 205.4%  
Book value per share (Unadj.) Rs292.9243.8 120.2%  
Shares outstanding (eoy) m119.57450.58 26.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.6 60.1%   
Avg P/E ratio x25.133.9 73.8%  
P/CF ratio (eoy) x21.828.2 77.3%  
Price / Book Value ratio x4.87.0 68.6%  
Dividend payout %22.614.9 151.6%   
Avg Mkt Cap Rs m168,653770,740 21.9%   
No. of employees `000NA16.4 0.0%   
Total wages/salary Rs m9,17121,077 43.5%   
Avg. sales/employee Rs ThNM8,379.6-  
Avg. wages/employee Rs ThNM1,289.0-  
Avg. net profit/employee Rs ThNM1,388.7-  
INCOME DATA
Net Sales Rs m49,915137,016 36.4%  
Other income Rs m1,6451,877 87.6%   
Total revenues Rs m51,561138,893 37.1%   
Gross profit Rs m8,48237,535 22.6%  
Depreciation Rs m1,0064,635 21.7%   
Interest Rs m671446 150.3%   
Profit before tax Rs m8,45134,330 24.6%   
Minority Interest Rs m-114-88 129.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60611,536 13.9%   
Profit after tax Rs m6,73122,707 29.6%  
Gross profit margin %17.027.4 62.0%  
Effective tax rate %19.033.6 56.6%   
Net profit margin %13.516.6 81.4%  
BALANCE SHEET DATA
Current assets Rs m27,06297,790 27.7%   
Current liabilities Rs m15,32453,872 28.4%   
Net working cap to sales %23.532.1 73.4%  
Current ratio x1.81.8 97.3%  
Inventory Days Days6785 78.5%  
Debtors Days Days41121 34.1%  
Net fixed assets Rs m12,61086,379 14.6%   
Share capital Rs m239901 26.5%   
"Free" reserves Rs m34,490105,735 32.6%   
Net worth Rs m35,027109,844 31.9%   
Long term debt Rs m1,21253,739 2.3%   
Total assets Rs m54,387224,378 24.2%  
Interest coverage x13.677.9 17.5%   
Debt to equity ratio x00.5 7.1%  
Sales to assets ratio x0.90.6 150.3%   
Return on assets %13.610.3 131.9%  
Return on equity %19.220.7 93.0%  
Return on capital %24.921.2 117.2%  
Exports to sales %12.949.1 26.4%   
Imports to sales %3.17.4 41.5%   
Exports (fob) Rs m6,46167,244 9.6%   
Imports (cif) Rs m1,54010,199 15.1%   
Fx inflow Rs m6,56371,405 9.2%   
Fx outflow Rs m3,01217,807 16.9%   
Net fx Rs m3,55253,598 6.6%   
CASH FLOW
From Operations Rs m7,259-3,690 -196.7%  
From Investments Rs m1,864-69,434 -2.7%  
From Financial Activity Rs m-9,27358,126 -16.0%  
Net Cashflow Rs m-150-14,998 1.0%  

Share Holding

Indian Promoters % 66.9 46.6 143.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 33.1 11.3 292.9%  
FIIs % 0.0 31.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.1 -  
Shareholders   68,381 98,259 69.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Aug 23, 2017 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - SHASUN PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS